This biopharmaceutical company has seen no estimate revision in the last 30 days. However, the Zacks Consensus Estimate has moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s rally can last.
Heron Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Investors interested in the Med-Drugs industry may consider better-ranked stocks like Aeolus Pharmaceuticals Inc. (AOLS), Ariad Pharmaceuticals Inc. (ARIA) and Aerie Pharmaceuticals, Inc. (AERI). All the three stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment